Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

Author:

Guenther Lyn12,Langley Richard G3,Shear Neil H.45,Bissonnette Robert6,Ho Vincent7,Lynde Charles89,Murray Eileen1011,Papp Kim12,Poulin Yves1314,Zip Catherine1516

Affiliation:

1. Department of Dermatology, University of Western Ontario, London, Ontario, Canada

2. The Guenther Dermatology Research Centre, 835 Richmond Street, London, Ontario, N6A 3H7, Canada

3. Division of Dermatogy, Department of Medicine, Dalhousie University and Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada

4. Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Centre, University of Toronto Medical School, Toronto, Ontario, Canada

5. Ventana Clinical Research Corporation, Toronto, Ontario, Canada

6. Innovaderm Research Inc., Montreal, Quebec, Canada

7. Department of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada

8. University Health Network, University of Toronto, Toronto, Ontario, Canada

9. Lynde Centre for Dermatology, Markham, Ontario, Canada

10. Department of Dermatology, University of Manitoba, Winnipeg, Manitoba, Canada

11. Winnipeg Clinic, Winnipeg, Manitoba, Canada

12. Probity Medical Research, Waterloo, Ontario, Canada

13. Department of Dermatology, Laval University, Sainte Foy, Quebec, Canada

14. Centre Dermatologique, Sainte Foy, Quebec, Canada

15. Department of Dermatology, University of Calgary, Calgary, Alberta, Canada

16. The Dermatology Centre, Calgary, Alberta, Canada

Abstract

Background: Approximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone.1,2 The severity of psoriasis ranges from mild to severe. It can lead to substantial morbidity and psychological stress and have a profound negative impact on patient quality of life.3,4 Although available therapies reduce therapies reduce the extent and severity of the disease and improve quality of life,3 reports have indicated a patient preference for more aggressive therapy and a dissatisfaction with the effectiveness of current treatment options.5 Objective: A Canadian Expert Panel, comprising Canadian dermatologists, convened in Toronto on 27 February 2004 to reach a consensus on unmet needs of patients treated with current therapies and how to include the pending biologic agents in and improve the current treatment algorithm for moderate-to-severe psoriasis. Current treatment recommendations suggest a stepwise strategy starting with topical agents followed by phototherapy and then systemic agents.3,6,7 The Panel evaluated the appropriate positioning of the biologic agents, once approved by Health Canada, for the treatment of moderate-to-severe psoriasis. Methods: The Panel reviewed available evidence and quality of these data on current therapies and from randomized, controlled clinical trials.8–14 Subsequently, consensus was achieved by small-group workshops followed by plenary discussion. Results: The Panel determined that biologic agents are an important addition to therapies currently available for moderate-to-severe psoriasis and proposed an alternative treatment algorithm to the current step wise paradigm. Conclusion: The Panel recommended a new treatment algorithm for moderate-to-severe psoriasis whereby all appropriate treatment options, including biologic agents, are considered together and patients' specific characteristics and needs are taken into account when selecting the most appropriate treatment option.

Publisher

SAGE Publications

Subject

Dermatology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3